106 research outputs found
Evaluation of the Role of Ethylene Vinyl Acetate on the Thermo-Mechanical Properties of PET/HDPE Blends
In this paper, blends of recycled polyethylene terephthalate (r-PET) and high-density polyethylene (HDPE) with and without a compatibilizer were prepared using a Brabender Haake Rheocord at 270°C and 32rpm. Ethylene vinyl acetate was chosen as the compatibilizer and its proportion was set to 5, 7, and 10 wt%. The thermal properties and crystallization behavior were determined by Differential Scanning Calorimetry (DSC). Micromechanical properties were also investigated using a Vickers microindentation tester. The DSC analysis indicates that the melting temperature of r-PET and HDPE in all the blends, compatibilized and uncompatibilized, remains constant and almost the same as those of the pure component. On the other hand, it is shown that the degree of crystallinity of HDPE in the blends calculated by DSC depends on the composition of the polymeric mixture. However, the Hardness (H) decreases with increasing r-PET content until 50/50 composition of r-PET/HDPE is reached, whereas for larger r-PET content values, H increases. The same trend was obtained with the addition of the compatibilizer
Role of a Compatibilizer in the Structure and Micromechanical Properties of Recycled Poly(ethylene terephthalate)/Polyolefin Blends with Clay
The comparison of the degree of crystallinity
and the micromechanical properties in the blends of recycled amorphous poly(ethylene terephthalate) (PET)with isotactic polypropylene (iPP) and high-density polyethylene (HDPE) with a compatibilizer in different proportions is reported. The physical study of the composites of the compatibilized blends and clay is also discussed. The analysis, performed by means of wide-angle X-ray scattering and differential scanning calorimetry techniques, permits us to describe, at microscale level, the role of the
compatibilizer on the structure and microhardness of the polymer blends that we studied. The results reveal that PET was incompatible with both iPP and HDPE. However,
the presence of the compatibilizer, a styrene–ethylene/butylene–styrene block copolymer grafted with maleic anhydride,
allowed the compatibilization of these polymers. In the PET/iPP blends, the clay seemed to have a nucleating effect on the iPP and also induced a hardness increase in the compatibilized blends. On the other hand, in case of PET/HDPE, the crystallinity of these samples (pure blends,blends with compatibilizer, and blends with compatibilizer plus clay) only depended on their composition. Similarly to the PET/iPP blends, the addition of clay induced an increase in the hardness of the ompatibilized blends.Peer reviewe
P16-37. HIV controllers with weak CD8+ T cell responses maintain a tight control of infection despite carrying infectious viruses
International audienc
Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level
There is evidence that HIV-positive injecting drug users benefit less than other risk groups from highly active antiretroviral therapy that has been available since 1996. In this multicentre European study the impact of the availability of highly active antiretroviral therapy on the progression rates to AIDS and death among injecting drug users with a documented date of HIV seroconversion is studied. After highly active antiretroviral therapy became available the risk of AIDS and death for injecting drug users decreased by 28% and 36%, which is less than has been reported for other risk group
Spread of Hepatitis C Virus among European Injection Drug Users Infected with HIV: A Phylogenetic Analysis
To describe the spread of hepatitis C virus (HCV) among HCV/human immunodeficiency virus (HIV)-coinfected injection drug users (IDUs), the molecular epidemiology of HCV was studied among 108 IDUs from 7 European countries. Phylogenetic analysis based on the NS5B region showed great sequence variation of HCV within each country and no clear phylogenetic clustering by geographic region. The most prevalent subtypes were 1a and 3a, but the percentage of genotype 4 was also relatively high, ranging from 7% in northern Europe to 24% in southern Europe. Genotype 4 consisted mainly of subtype 4d and has entered the majority of the IDU populations studied. The significantly lower evolutionary distances within subtype 4d suggest that this subtype may have entered the European IDU population relatively recently. In conclusion, HCV exchange between European IDU populations has occurred on a large scale, and, overall, country-specific clustering for HCV was less than that shown for HI
Divergent adaptive immune responses define two types of long COVID
BackgroundThe role of adaptive immune responses in long COVID remains poorly understood, with contrasting hypotheses suggesting either an insufficient antiviral response or an excessive immune response associated with inflammatory damage. To address this issue, we set to characterize humoral and CD4+ T cell responses in long COVID patients prior to SARS-CoV-2 vaccination.MethodsLong COVID patients who were seropositive (LC+, n=28) or seronegative (LC-, n=23) by spike ELISA assay were recruited based on (i) an initial SARS-CoV-2 infection documented by PCR or the conjunction of three major signs of COVID-19 and (ii) the persistence or resurgence of at least 3 symptoms for over 3 months. They were compared to COVID patients with resolved symptoms (RE, n=29) and uninfected control individuals (HD, n=29).ResultsThe spectrum of persistent symptoms proved similar in both long COVID groups, with a trend for a higher number of symptoms in the seronegative group (median=6 vs 4.5; P=0.01). The use a highly sensitive S-flow assay enabled the detection of low levels of SARS-CoV-2 spike-specific IgG in 22.7% of ELISA-seronegative long COVID (LC-) patients. In contrast, spike-specific IgG levels were uniformly high in the LC+ and RE groups. Multiplexed antibody analyses to 30 different viral antigens showed that LC- patients had defective antibody responses to all SARS-CoV-2 proteins tested but had in most cases preserved responses to other viruses. A sensitive primary T cell line assay revealed low but detectable SARS-CoV-2-specific CD4 responses in 39.1% of LC- patients, while response frequencies were high in the LC+ and RE groups. Correlation analyses showed overall strong associations between humoral and cellular responses, with exceptions in the LC- group.ConclusionsThese findings provide evidence for two major types of antiviral immune responses in long COVID. Seropositive patients showed coordinated cellular and humoral responses at least as high as those of recovered patients. In contrast, ELISA-seronegative long COVID patients showed overall low antiviral responses, with detectable specific CD4+ T cells and/or antibodies in close to half of patients (52.2%). These divergent findings in patients sharing a comparable spectrum of persistent symptoms raise the possibility of multiple etiologies in long COVID
Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers
Despite long-lasting HIV replication control, a significant proportion of elite controller (EC) patients may experience CD4 T-cell loss. Discovering perturbations in immunological parameters could help our understanding of the mechanisms that may be operating in those patients experiencing loss of immunological control.
Methods A case–control study was performed to evaluate if alterations in different T-cell homeostatic parameters can predict CD4 T-cell loss in ECs by comparing data from EC patients showing significant CD4 decline (cases) and EC patients showing stable CD4 counts (controls). The partial least-squares–class modeling (PLS-CM) statistical methodology was employed to discriminate between the two groups of patients, and as a predictive model.
Results
Herein, we show that among T-cell homeostatic alterations, lower levels of naĂŻve and recent thymic emigrant subsets of CD8 cells and higher levels of effector and senescent subsets of CD8 cells as well as higher levels of exhaustion of CD4 cells, measured prior to CD4 T-cell loss, predict the loss of immunological control.
Conclusions
These data indicate that the parameters of T-cell homeostasis may identify those EC patients with a higher proclivity to CD4 T-cell loss. Our results may open new avenues for understanding the mechanisms underlying immunological progression despite HIV replication control, and eventually, for finding a functional cure through immune-based clinical trials.projects RD12/0017/0031, RD16/0025/
0013, and SAF2015-66193-R as part of the Health Research and Development
Strategy, State Plan for Scientific and Technical Research and Innovation (2008–
2011 and 2013–2016) and cofinanced by the Institute of Health Carlos III (ISCIII),
Sub-Directorate General for Research Assessment and Promotion and European
Regional Development Fund. NR is a Miguel Servet investigator from the ISCIII
(CP14/00198), Madrid, Spain. C Restrepo was funded by project RD12/0017/
0031 and is currently funded by project RD16/0025/0013. M GarcĂa is a
predoctoral student co-funded by grant CP14/00198 and an Intramural
Research Scholarship from Instituto de Investigación Sanitaria-Fundación Jiménez
DĂaz (IIS-FJD)
Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved?
Objective: This article compares trends in CD4+ T-cell recovery and proportions achieving optimal restoration (>=500 cells/µl) after viral suppression following combination antiretroviral therapy (cART) initiation between rapid and nonrapid progressors. Methods: We included HIV-1 seroconverters achieving viral suppression within 6 months of cART. Rapid progressors were individuals experiencing at least one CD4+ less than 200 cells/µl within 12 months of seroconverters before cART. We used piecewise linear mixed models and logistic regression for optimal restoration. Results: Of 4024 individuals, 294 (7.3%) were classified as rapid progressors. At the same CD4+ T-cell count at cART start (baseline), rapid progressors experienced faster CD4+ T-cell increases than nonrapid progressors in first month [difference (95% confidence interval) in mean increase/month (square root scale): 1.82 (1.61; 2.04)], which reversed to slightly slower increases in months 1–18 [-0.05 (-0.06; -0.03)] and no significant differences in 18–60 months [-0.003 (-0.01; 0.01)]. Percentage achieving optimal restoration was significantly lower for rapid progressors than nonrapid progressors at months 12 (29.2 vs. 62.5%) and 36 (47.1 vs. 72.4%) but not at month 60 (70.4 vs. 71.8%). These differences disappeared after adjusting for baseline CD4+ T-cell count: odds ratio (95% confidence interval) 0.86 (0.61; 1.20), 0.90 (0.38; 2.17) and 1.56 (0.55; 4.46) at months 12, 36 and 60, respectively. Conclusion: Among people on suppressive antiretroviral therapy, rapid progressors experience faster initial increases of CD4+ T-cell counts than nonrapid progressors, but are less likely to achieve optimal restoration during the first 36 months after cART, mainly because of lower CD4+ T-cell counts at cART initiation
Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 Study
Previous studies of the HIV-1 disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load. We performed a Genome Wide Association study in a cohort of 605 HIV-1-infected seroconverters for detection of novel genetic factors that influence plasma HIV-RNA and cellular HIV-DNA levels. Most of the SNPs strongly associated with HIV-RNA levels were localised in the 6p21 major histocompatibility complex (MHC) region and were in the vicinity of class I and III genes. Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers. Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene). Our data provide evidence that the MHC controls both HIV replication and HIV reservoir. They also indicate that two additional genomic loci may influence the HIV reservoir
Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery
Virally suppressed HIV-positive individuals on combination antiretroviral therapy who do not achieve a CD4 count >200 cells/µL have substantially increased long-term mortality. The increased mortality was seen across different patient groups and for all causes of deat
- …